Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced its financial results for the third quarter ended September 30, 2026, reporting total revenues of $1.123 billion. This figure represents a 41% year-over-year increase compared to the $795 million reported in the same period of 2025. The company noted that this is the first time net product sales have exceeded $1 billion in a single quarter.
Revenue growth was driven by the company’s three primary product offerings. INGREZZA (valbenazine) generated $801 million in net product sales, a 17% increase from the prior year. CRENESSITY (crinecerfont) contributed $211 million in sales, reflecting a 115% year-over-year growth. VYKAT XR (diazoxide choline) XR, following its acquisition of Soleno Therapeutics in May 2026, generated $107 million in net product sales.
Neurocrine updated its financial guidance for 2026. The company raised its full-year 2026 net product sales guidance for INGREZZA to a range of $2.9 billion to $2.925 billion, up from the previous estimate of $2.825 billion to $2.875 billion.
On the balance sheet, as of September 30, 2026, the company held $790 million in cash, cash equivalents, and marketable securities. The company reported GAAP net income of $207 million and diluted earnings per share of $1.96 for the third quarter of 2026, compared to $210 million and $2.04, respectively, in the prior year.
In corporate news, the company announced the initiation of a Phase 1 first-in-human clinical study evaluating NBIP-’1968, a GLP-1/GIP/glucagon receptor triple agonist for obesity. Additionally, a Phase 2 study was launched for NBI-’567, an M1/M4 muscarinic agonist for cognitive impairment in Alzheimer’s disease. The company also announced that Eiry W. Roberts, M.D., has rejoined the company as Chief Medical Officer.
